A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Conditions: Metastatic Breast Cancer

Interventions: Drug: Lenvatinib; Drug: Pembrolizuma; Drug: Fulvestrant

Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 2, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments